Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 07'th Mar 2025
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting
09:30am, Friday, 28'th Feb 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2025--Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting.
Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration
08:00am, Thursday, 20'th Feb 2025
WILMINGTON, Del. & BURLINGAME, Calif.--(BUSINESS WIRE)--Incyte and Genesis Therapeutics announce strategic AI-focused research collaboration.
Incyte to Present at Upcoming Investor Conferences
08:00am, Tuesday, 18'th Feb 2025
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: Cowen 45th Annual Health Care Conference o
Reevaluating Incyte Corporation After Earnings (Technical Analysis)
08:30am, Wednesday, 12'th Feb 2025
Incyte's recent earnings call disappointed the market, causing a 10.52% drop, but management's bullish comments and no debt position suggest a promising future. Technically, INCY is currently below it
Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025
07:30am, Tuesday, 11'th Feb 2025
Incyte's Q4 2024 earnings showed mixed results with slight revenue beat but missed non-GAAP earnings estimates. The stock has declined due to 2025 guidance coming below expectations. Despite slowing
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
11:56am, Monday, 10'th Feb 2025
Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year sales.
Incyte Corporation (INCY) Q4 2024 Earnings Call Transcript
11:52am, Monday, 10'th Feb 2025
Incyte Corporation (NASDAQ:INCY ) Q4 2025 Earnings Conference Call February 10, 2025 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Ex
Incyte (INCY) Reports Q4 Earnings: What Key Metrics Have to Say
10:31am, Monday, 10'th Feb 2025
Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Stree
Incyte (INCY) Q4 Earnings Miss Estimates
09:15am, Monday, 10'th Feb 2025
Incyte (INCY) came out with quarterly earnings of $1.43 per share, missing the Zacks Consensus Estimate of $1.53 per share. This compares to earnings of $1.06 per share a year ago.
Incyte reports quarterly sales above estimates on strong demand for key drugs
08:38am, Monday, 10'th Feb 2025
Drugmaker Incyte Corp reported fourth-quarter revenue above Wall Street estimates on Monday, boosted by strong demand for its key blood-cancer drug Jakafi and skin-disorder treatment Opzelura.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones.
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 07'th Feb 2025
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Curious about Incyte (INCY) Q4 Performance? Explore Wall Street Estimates for Key Metrics
10:21am, Wednesday, 05'th Feb 2025
Besides Wall Street's top -and-bottom-line estimates for Incyte (INCY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the qua
Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know
12:50pm, Tuesday, 04'th Feb 2025
INCY's fourth-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.
